The inhibition of PARP1 together with temozolomide may overcome the acquired resistance of GBM cells on temozolomide [52] which also counteracted gliomagenesis by inducing mitotic catastrophe and homologous recombination repair deficiency in PTEN‐mutant glioma [53]. The gene discussed is PARP1; the disease is central nervous system cancer.